REQUEST A DEMO
Total
USD $0.00
Search more companies

Eutilex Co.,Ltd. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Eutilex Co.,Ltd. Profile Updated: July 06, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies. The Company was established on February 27, 2015. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 24, 2018.

Headquarters
1401, 25, Gasan Digital 1-Ro, Geumcheon-Gu
Seoul; Seoul;

Contact Details: Purchase the Eutilex Co.,Ltd. report to view the information.

Website: http://www.eutilex.com

Basic Information
Total Employees:
Purchase the Eutilex Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Eutilex Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Eutilex Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Eutilex Co.,Ltd. report to view the information.
Incorporation Date:
February 27, 2015
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
19.1%
Purchase this report to view the information.
16.8%
Purchase this report to view the information.
8.8%
Subsidiaries
Eutilogics Inc
Company Performance
Financial values in the chart are available after Eutilex Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
738.27%
Total operating revenue
574.45%
Operating profit (EBIT)
16.63%
EBITDA
28.84%
Net Profit (Loss) for the Period
16.89%
Total assets
-23.54%
Total equity
-31.69%
Operating Profit Margin (ROS)
18795.48%
Net Profit Margin
17991.88%
Return on Equity (ROE)
-1.94%
Debt to Equity Ratio
7.93%
Quick Ratio
-3.38%
Cash Ratio
-1.53%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?